Clinical Trial

A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.

Study acronym: PEGASUS
Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 8, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
PEGASUS aims to test acceptability and feasibility of studying phenoconversion (the change in metabolism phenotype) using probe medications in a paediatric oncology patient population. The study will be conducted in patients (6-25 years of age) with Hodgkin lymphoma or non-Hodgkin lymphoma as exemplar cohort, but with the understanding that cancer-directed and supportive care medicines of the CYP3A4, CYP2C19, and CYP2D6 metabolic pathways are commonly utilised for the treatment of many paediatric, adolescent, young adult, and adult cancers. The study involves administration of the probe medication at timepoints which align with pre-determined hospital visits for the treatment of lymphoma and subsequent blood draws to measure the metabolism of the probe medications. The acceptability and feasibility of this study will inform future studies in phenoconversion within the paediatric cancer population to direct more personalised precision medicine.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-04-20; most recent amendment 2025-09-01.
Status change: Not Yet Recruiting → Recruiting 2025-09-01
Trial Details
NCT Number NCT06383338
Lead Sponsor Murdoch Childrens Research Institute
Conditions Hodgkin Lymphoma, Non Hodgkin Lymphoma
Enrollment 10 participants
Start Date 2025-07-22
Primary Completion 2026-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2025-09-08